Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 17

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.

Dementia Alzheimer's type

Recruiting

Study on Flutemetamol (18F) for Detecting Amyloid Pathology in Cognitively Normal Elderly at Risk for Alzheimer's Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years · Healthy volunteers
  • Substances:Flutemetamol (18F)
  • Sponsor:Amsterdam UMC Stichting

Migraine

Recruiting

Study on Eptinezumab for Migraine: Understanding How It Works and Finding Patient Response Markers for Migraine Sufferers

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Eptinezumab
  • Sponsor:Ospedale San Raffaele S.r.l.

Huntington's disease

Recruiting

Study on [18F]MNI-659 to Track Huntington's Disease Progression in Symptomatic and Pre-symptomatic Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE
  • Sponsor:Assistance Publique Hopitaux De Paris

Multiple sclerosis

Recruiting

Study of [18F]-DPA-714 PET imaging to assess neuroinflammation in multiple sclerosis patients compared to healthy controls

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Rabies+1

Recruiting

Study on Pain and Usability of Rabies Vaccine Injection Techniques in Children Aged 4-14 Using Inactivated Rabies Virus (Strain Flury LEP)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Institute Of Tropical Medicine

Rabies+1

Recruiting

Study of Single-Dose Rabies Vaccine (Inactivated Flury LEP Strain) Immunity After Five Years: Testing Booster Response in Previously Vaccinated Adults

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Dementia Alzheimer's type

Recruiting

Study on How Florquinitau (18F) Affects Brain Circuits in Early Alzheimer's Disease Stages

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florquinitau (18F)
  • Sponsor:UZ Leuven

Dementia Alzheimer's type

Recruiting

Study of Flortaucipir (18F) PET Imaging in Healthy Elderly Twins to Investigate Early Signs of Alzheimer's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years · Healthy volunteers
  • Substances:Flortaucipir (18F)
  • Sponsor:Amsterdam UMC Stichting

Autism spectrum disorder

Recruiting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Dementia Alzheimer's type

Recruiting

A study using [18F]RO6958948 PET imaging to examine brain tau protein deposits in people at risk of Alzheimer's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole
  • Sponsor:Barcelonabeta Brain Research Center

Craniocerebral injury

Recruiting

Study on Dopaminergic Pathway Disruption in Comatose Patients with Traumatic Brain Injury Using [18F]LBT-999

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Inserm

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.